Ranbaxy launches first generic Lipitor backed by profit-sharing pact with Teva
This article was originally published in Scrip
Executive Summary
After months of speculation, the climax to the 'thriller' concerning the first Lipitor (atorvastatin) generic on the US market played out somewhat along expected lines. Ranbaxy Laboratories has launched its generic atorvastatin in the US backed by an FDA approval and a profit-sharing pact with Teva Pharmaceuticals, while Watson's authorised generic also hit the market on schedule.